Anika Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Express News | Anika Therapeutics Inc : Stephens Raises Target Price to $24 From $22
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Call Transcript
Express News | Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Anika Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 32.14% Barrington Research $37 → $37 Maintains Outperform 03/14/2024 32.14% Barrington Research
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Names Steve Griffin as New Finance Chief
By Mary de Wet Anika Therapeutics appointed Steve Griffin as chief financial officer, executive vice president and treasurer, effective June 3. Griffin, the former finance chief for VSE, succeeds Mi
Express News | Anika Says Cost Reduction Initiatives Complete; Says On-Track For FY24 Revenue Guidance Of $168M-$173M (Est $170.272M)
Anika Announces Steve Griffin Appointed To CFO, Effective June 3, 2024
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice Presi
Anika Therapeutics | 10-Q: Quarterly report
Express News | Anika Therapeutics Inc Sees Adjusted Ebitda for 2024 to Be $25 to $30 Million
Express News | Anika Therapeutics Inc Sees Revenue for Fiscal Year 2024 of $168 to $173 Million
Anika Therapeutics Appoints Steve Griffin as Finance Chief
Anika Therapeutics Announces New CFO and Executive Changes
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09
04:14 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, Vs. Street Est of $39.1M
04:13 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, vs. Street Est of $39.1M
Express News | Anika Therapeutics Q1 2024 Adj EPS $0.09 Beats $(0.19) Estimate, Sales $40.523M Beat $39.143M Estimate
Anika Therapeutics Former CFO Michael Levitz Will Remain With Co Through Dec 31 >ANIK
Anika Therapeutics Former CFO Michael Levitz Will Remain With Co Through Dec 31 >ANIK
Anika Therapeutics Appoints Steve Griffin as CFO Effective June 3 >ANIK
Anika Therapeutics Appoints Steve Griffin as CFO Effective June 3 >ANIK